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Background: To investigate the sensitivity of various gamma criteria used in the gamma-index method for
patient-specific volumetric modulated arc therapy (VMAT) quality assurance (QA) for stereotactic body radiation
therapy (SBRT) using a flattening filter free (FFF) photon beam.
Methods: Three types of intentional misalignments were introduced to original high-definition multi-leaf collimator
(HD-MLC) plans. The first type, referred to Class Out, involved the opening of each bank of leaves. The second type, Class
In, involved the closing of each bank of leaves. The third type, Class Shift, involved the shifting of each bank of leaves
towards the ground. Patient-specific QAs for the original and the modified plans were performed with MapCHECK2 and
EBT2 films. The sensitivity of the gamma-index method using criteria of 1%/1 mm, 1.5%/1.5 mm, 1%/2 mm, 2%/1 mm
and 2%/2 mm was investigated with absolute passing rates according to the magnitudes of MLCs misalignments. In
addition, the changes in dose-volumetric indicators due to the magnitudes of MLC misalignments were investigated. The
correlations between passing rates and the changes in dose-volumetric indicators were also investigated using
Spearman’s rank correlation coefficient (γ).
Results: The criterion of 2%/1 mm was able to detect Class Out and Class In MLC misalignments of 0.5 mm and Class
Shift misalignments of 1 mm. The widely adopted clinical criterion of 2%/2 mm was not able to detect 0.5 mm MLC
errors of the Class Out or Class In types, and also unable to detect 3 mm Class Shift errors. No correlations were observed
between dose-volumetric changes and gamma passing rates (γ < 0.8).
Conclusions: Gamma criterion of 2%/1 mm was found to be suitable as a tolerance level with passing rates of 90% and
80% for patient-specific VMAT QA for SBRT when using MapCHECK2 and EBT2 film, respectively.
Keywords: Patient-specific quality assurance, Stereotactic body radiation therapy, Gamma-index method, Dose-volumetric
indicator, High-definition multi-leaf collimatorBackground
A widely-adopted patient-specific quality assurance (QA)
method for intensity modulated radiation therapy (IMRT)
is the delivery of a verification plan, which is identical to
the treatment plan, to a phantom loaded with a two-
dimensional (2D) dosimeter. The measured 2D dose distri-
bution is then compared to the distribution calculated by a
treatment planning system (TPS) [1]. When comparing the* Correspondence: leodavinci@naver.com
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unless otherwise stated.2D dose distributions, the gamma-index method suggested
by Low et al. is generally used in the clinic and IMRT plans
are evaluated with gamma passing rates [2]. This QA
method for IMRT has also been applied to patient-specific
QA for volumetric modulated arc therapy (VMAT). Al-
though VMAT is different in many respects from IMRT,
the criterion of 3%/3 mm has typically been used for
gamma evaluation for both IMRT and VMAT QA [1,3-9].
Recent studies have raised the question of whether or not
the criterion of 3%/3 mm for VMAT QA is clinically rele-
vant [10-12]. Heilemann et al. recommended a stricter
gamma criterion of 2%/2 mm rather than 3%/3 mm for a
patient-specific VMAT QA [13]. Similarly, Fredh et al.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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simeters and concluded that a criterion of 2%/2 mm rather
than 3%/3 mm should be used clinically [14].
As previously mentioned, several studies have recently
been performed that investigated patient-specific VMAT
QA for conventional fractionated radiation therapy
[14-16]. However, thus far no study has been performed
to investigate VMAT QA results for stereotactic body ra-
diation therapy (SBRT) in connection with high-definition
MLC (HD-MLC) positioning errors in TrueBeam STx
(version 1.6, Varian Medical Systems, Palo Alto, CA, USA)
while using flattening filter free (FFF) mode. LoSasso et al.
have demonstrated that dose error is inversely propor-
tional to the mean MLC gap [17]. The same magnitudes
of errors introduced in MLCs might affect the dose distri-
bution of SBRT differently than that of conventional
radiotherapy since an indication for SBRT is generally a
small localized tumor [18]. Thus, the criterion of 2%/
2 mm suggested by the recent studies for patient-specific
VMAT QA is already widely-adopted for SBRT VMAT
QA in many institutions [18].
In this study, we investigated the sensitivity of the
gamma-index method with various gamma criteria by
introducing intentional HD-MLC misalignments for
SBRT in the FFF mode. The clinical relevance was evalu-
ated by analysing changes in the dose volume histograms
(DVH) of each structure.
Methods
Patient selection and simulation
After approval from an institutional review board (IRB,
Seoul National University Hospital Human Research Pro-
tection Program Center), a total of 20 patients who under-
went SBRT for either lung cancer (10 patients) or
localized spine metastasis (10 patients) were selected for
this study. All patients underwent CT scans using a Bril-
liance CT Big Bore™ (Philips, Amsterdam, Netherlands).
The slice thicknesses of CT images for patients with lung
cancer, and for localized spine metastasis were 2 mm and
1.5 mm, respectively. Four-dimensional CT images were
acquired to allow delineation of internal target volume
(ITV) for lung SBRT.
Treatment planning of VMAT for SBRT
The VMAT plans for SBRT were generated using Eclipse™
(Varian Medical Systems, Palo Alto, USA) with 6 MV FFF
photon beams for lung SBRT and 10 MV FFF photon
beams for spine SBRT. TrueBeam STx with HD-MLC was
used for the SBRT planning. Optimizations were performed
with a progressive resolution optimizer 3 (PRO3, version
A10) algorithm and dose distributions were calculated
using the anisotropic analytic algorithm (AAA, version
A10) with a calculation grid of 1 mm for the lung SBRT
and 2 mm for the spine SBRT. The prescribed dose for lungSBRT was 48 Gy (12 Gy/fraction) with the exception of 2
cases where prescribed doses were 54 Gy and 60 Gy
(13.5 Gy/fraction and 15 Gy/fraction). For spine SBRT,
there were various prescribed doses ranging from 14 Gy to
30 Gy in 1 to 3 fractions. Single arc with full or partial rota-
tion of the gantry was used for lung SBRT, while either sin-
gle or two arcs were used for spine SBRT. The average
value of monitor units (MUs) per cGy for the lung SBRT
plans was 2.54, while that of the spine SBRT plans was
2.68. For lung SBRT plans at least 95% of the prescribed
dose was delivered to 100% of the target volume, while for
spine SBRT plans 100% of the prescribed dose was deliv-
ered to at least 90% of the target volume.
Simulation of MLC misalignments in VMAT plans for SBRT
The original VMAT plans were exported from the TPS in
DICOM format and then imported into an in-house
program written in Matlab (version 8.1, Mathworks Inc.,
Natick, MA, USA), which allowed modification of the
MLC movement. Three types of MLC misalignments were
introduced to each VMAT plan (Figure 1). The first type,
named Class Out, was a simulation where both MLCs
were opened by 0.25 mm, 0.5 mm, 1 mm and 2 mm in an
isoplane leading to larger openings of MLC apertures. The
second type, Class In, was a simulation where both MLCs
were closed by 0.25 mm, 0.5 mm, 1 mm and 2 mm lead-
ing to smaller openings of MLC apertures. The third type,
Class Shift, was intended to simulate the effect of gravita-
tional forces on MLCs. Both MLC banks were shifted in
the same direction towards the ground with respect to the
gantry angle by 1 mm, 2 mm and 3 mm. For each patient,
11 modified plans and 1 original plan were generated (12
plans per patient).
To eliminate the effect of the jaw tracking function of
TrueBeam STx on dose distributions, the positions of the
jaws were set to be identical for all the modified and ori-
ginal plans. Since the minimum dynamic leaf gap is fixed at
0.5 mm by the manufacturer, if the results of the modifica-
tion for the Class In error were less than 0.5 mm, they were
set to be 0.5 mm. Even though the manufacturer of the
HD-MLC specifies that the positioning accuracy in terms
of end accuracy is 1 mm, we introduced MLC errors of up
to 2 mm for both Class In and Class Out because the value
of dynamic leaf tolerance was set to be 2 mm in our institu-
tion, following recommendations from LoSasso et al. [17].
For Class Shift, MLC errors of up to 3 mm were simulated
in order to consider not only the MLC positioning errors,
but also the MLC bank positioning errors due to gravita-
tional force. The modified plans were imported back to the
TPS and dose distributions were calculated with each pa-
tient’s CT image sets using a calculation grid of 1 mm. The
changes in DVHs of each structure in the modified plans
were reviewed by radiation oncologists to determine if the
changed DVHs were clinically acceptable or not.
Figure 1 Three types of MLC misalignments introduced to each SBRT plan delivered with VMAT technique. The first type named as Class
Out was a simulation that both multi-leaf collimators (MLCs) were opened (a) while the second type named as Class In was a simulation that
both MLCs were closed (b). The third type named as Class Shift was a simulation that both MLC banks were shifted in the same direction toward
ground. MLC misalignments of Class Shift during gantry rotation from 180° to 0° (c) and from 0° to 180° (d) in the IEC scale are shown.
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The planar dose distributions of each plan were measured
with a MapCHECK2 detector array (Sun Nuclear Corpor-
ation, Melbourne, FL, USA) and EBT2 film (Ashland Inc.,
Covington, KY, USA). For gamma evaluations with Map-
CHECK2, CT images of the MapCHECK2 detector array
inserted into a MapPHAN (Sun Nuclear Corporation,
Melbourne, FL, USA) were acquired with a slice thickness
of 1 mm. The reference dose distributions of each original
VMAT plan were calculated using those CT images with a
calculation grid of 1 mm which is the finest resolution in
Eclipse™. Similarly, for gamma evaluations with EBT2 films,
CT images of a solid water phantom (Gammex, Middleton,
WI, USA) with a slice thickness of 1 mm were acquired
and the reference dose distributions were calculated using
those CT images with a calculation grid of 1 mm (30 cm×
30 cm× 10 cm) [2]. The original and modified VMAT
plans were delivered by TrueBeam STx which was cali-
brated before delivery to keep the output deviation less
than 0.1% following the AAPM TG-51 protocol [19]. The
absolute dose and the responses of MapCHECK2 and
EBT2 films were also calibrated before measurements. The
size of the EBT2 film was 8 × 8 cm2 for the lung QA, and
12 × 12 cm2 for the spine QA. The EBT2 film was placed
between two pieces of solid water phantom at 5 cm depth
and the isocenter was located at the center of the phantom.
Film dosimetry carefully followed the self-developing pro-
cedure recommended by manufacturer. Three separatebatches of EBT2 film were used for the measurements to
avoid the inter-batch response variation of EBT2 films. The
films from each batch-numbered packet were used for each
calibration. The EBT2 films were scanned 20 hours after ir-
radiation using a flatbed scanner (Epson 10000XL, Epson
Canada Ltd., Toronto, Ontario, Canada) in 48 bit color
mode (i.e., RGB mode). The practical spatial resolution of
the scans was 75 dpi. The dual channel method for red and
blue correction and scanner uniformity correction was ap-
plied for calibration. The calibration curve was acquired in
the range of 0 to 26 Gy. The measured values of optical
density were converted into a dose map using the RIT 113
film dosimetry system (version 6.0, Radiological Imaging
Technology Inc., Colorado Springs, CO, USA). The calcu-
lated and measured dose distributions were also compared
using the RIT 113 software. The calculated dose distribu-
tions were registered to the measured dose distributions
with best fit method. For each patient a rectangular region
of interest (ROI) was defined which covered not only the
target area, but also the area below 10% of the maximum
dose.
In the case of MapCHECK2, SNC patient software
(version 6.1.2, Sun Nuclear Corporation, Melbourne, FL,
USA) was used for analysis of the measurements. The
calculated dose distributions with TPS were registered to
the measured dose distributions by matching isocenter
of the calculated dose distributions to the origin of the
measured dose distributions.
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The absolute gamma analyses were performed using mea-
surements from both MapCHECK2 and EBT2 films. The
global gamma-index was used and the points with doses
less than 10% of the maximum dose were ignored to reduce
the effect of noise [20,21]. The gamma criteria of 1%/1 mm,
1.5%/1.5 mm, 1%/2 mm, 2%/1 mm and 2%/2 mm were
used and the passing rates of each criterion vs. magnitudes
of MLC misalignments were evaluated. Since various
gamma criteria were tested in the present study, the passing
rate was fixed to allow for direct comparisons to be made.
The tolerance level of the passing rate was set to be 90%
which is used in our institution as well as generally cited in
the literature [22]. Linear regressions were used to find the
lines of best fit for the results of the gamma passing rates
vs. MLC misalignments. The gradients of the lines of best
fit were compared one another to evaluate the sensitivity of
each gamma criterion. The DVHs of the original VMAT
plans were compared to those of the modified VMAT plans
to investigate the effects of MLC misalignment on dose dis-
tributions. The changes in DVHs according to both type
and magnitude of MLC misalignments were each reviewed
by a radiation oncologist whose specialty is lung and spineFigure 2 Decreases of the absolute gamma passing rates according t
Class In and Class Shift using MapCHECK2 in lung stereotactic body radiatio
spine plans are shown in (b), (f) and (j), respectively. The results at Class O
shown in (c), (g) and (k) while those in spine plans are shown in (d), (h) aSBRT. Clinically tolerable magnitudes of MLC misalign-
ments were then determined for each type of MLC mis-
alignment. The correlations between gamma passing rates
of each criterion and the dose-volumetric changes in the
target volume were investigated using Spearman’s rank cor-
relation coefficient (γ). With a passing rate of 90% as a tol-
erance level, the receiver operating characteristic (ROC)
curves and the values of area under curve (AUC) were ac-
quired for each tested gamma criterion.Results
Passing rates of gamma-index method with various
gamma criteria with respect to the magnitudes of MLC
misalignments
The relationships between the absolute gamma passing
rates vs. MLC misalignments of Class Out, Class In and
Class Shift with various criteria using MapCHECK2 and
EBT2 films are illustrated in Figure 2. The gradients ac-
quired from the lines of best fit of the passing rates with
respect to the magnitudes of MLC misalignments are
shown in Table 1. Higher absolute values of the gradient
indicate higher sensitivity of gamma evaluation, thus theo the magnitudes of MLC misalignments. The results at Class Out,
n therapy (SBRT) plans are shown in (a), (e) and (i) while those in
ut, Class In and Class Shift using EBT2 films in lung SBRT plans are
nd (l), respectively.
Table 1 Gradients of best-fitting lines by linear regression of the absolute passing rates vs. MLC misalignments
1%/1 mm 1.5%/1.5 mm 1%/2 mm 2%/1 mm 2%/2 mm
Class Out (mm/%)
MapCHECK2 Lung −37.7 −29.8 −30.3 −32.4 −15.5
Spine −41.5 −16.0 −22.6 −27.8 −5.1
EBT2 Lung −31.6 −36.5 −30.8 −39.5 −26.3
Spine −28.0 −34.2 −30.9 −35.4 −29.5
Class In (mm/%)
MapCHECK2 Lung −37.9 −26.5 −24.3 −33.1 −10.9
Spine −41.1 −24.4 −20.4 −35.4 −12.6
EBT2 Lung −30.5 −36.2 −32.6 −38.0 −30.1
Spine −28.3 −31.4 −28.2 −33.6 −25.8
Class Shift (mm/%)
MapCHECK2 Lung −12.4 −9.6 −7.9 −11.3 −5.2
Spine −8.3 −3.9 −3.4 −5.9 −2.5
EBT2 Lung −9.4 −8.4 −6.6 −11.0 −5.8
Spine −7.5 −7.1 −6.0 −8.3 −5.2
Abbreviation: MLC multi-leaf collimator A higher absolute gradient means the test criteria are more sensitive to detect MLC misalignments.
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was 1%/1 mm, and 2%/1 mm from EBT2 film.
For the MapCHECK2 results, the passing rates of the
original plan with the criterion of 1%/1 mm were less
than 90%. If a passing rate of 80% was applied as a toler-
ance level for 1%/1 mm criterion, MLC misalignments
of 0.5 mm or less for Class In and Class Out, and 2 mm
or less for Class Shift were not detectable. On the other
hand, 2%/1 mm, which was the second most sensitive
criterion with MapCHECK2, was able to detect 0.5 mm
MLC misalignments for Class In and Class Out, and
1 mm for Class Shift with a passing rate of 90%. Gamma
evaluations with the criteria of 1.5%/1.5 mm and 1%/
2 mm were not sensitive enough to detect MLC mis-
alignment up to 0.5 mm for Class In and Class Out, or
up to 1 mm for Class Shift. The criterion of 2%/2 mm
was the least sensitive.
The passing rates of EBT2 films were much lower than
those of MapCHECK2. With the exception of the 2%/
2 mm criterion, no criterion satisfied the passing rate of
90%. Therefore, a new tolerance level lower than 90%
should be established for use of EBT2 films for VMAT.
The most sensitive gamma criterion with EBT2 film was
2%/1 mm and it was able to detect MLC misalignment
of 0.5 mm for Class In and Class Out, and 1 mm for
Class shift with a passing rate of 80% as a tolerance level,
showing the same performance as 2%/1 mm in the Map-
CHECK2 results.
The sensitivities of the gamma-index method with
MapCHECK2 were higher in the lung plans than in the
spine plans at all gamma criteria except 1%/1 mm for
Class Out and 1%/1 mm, 2%/1 mm and 2%/2 mm forClass In. In the case of EBT2 films, the sensitivities in
lung plans were higher than those in the spine plans in
all cases except 1%/2 mm and 2%/2 mm for Class Out.
For Class Shift, the sensitivities in the lung plans were
always higher than those in the spine plans at all criteria
with both MapCHECK2 and EBT2 films.
Dose-volumetric changes with respect to the magnitudes
of MLC misalignments for lung SBRT plans
The percent differences of dose-volumetric indicators
with respect to the magnitudes of MLC misalignments
in lung SBRT for Class Out, Class In and Class Shift are
shown in Table 2 [23]. Since the kind of OARs which
should be considered was different for each SBRT plan
according to the tumor location, the evaluated numbers
of plans (N) were not always same. The percent differ-
ence was calculated as
%diff ¼ 100 Values of Modified plan−Values of original plan
Value of original plan
In the case of Class Out, the doses delivered to both
the target and the OARs were larger than those of the
original plan since the sizes of MLC apertures were in-
creased. Compared to the original plan, with a 0.5 mm
MLC misalignment the averaged value of the normal
lung volume that was irradiated by a dose larger than
12.4 Gy and 11.6 Gy was increased by 33.1% and 9.3%,
respectively. With a 0.5 mm MLC misalignment, the av-
eraged value of the maximum dose delivered to the
spinal cord and heart was increased by 3.5% and 5.4%,
respectively. In the case of Class In, the dose delivered
Table 2 The changes of dose-volumetric indicators according to the magnitudes of MLC misalignments in lung SBRT plans
Percent differences compared to the original plan (%)
MLC error (mm) Class Target Organs at risk
V90% D95% Mean Trachea Max SC Max Rib Max Lung V12.4Gy Lung V11.6Gy Heart Max Esophagus Max
N 10 10 10 7 10 9 10 10 10 10
0.25 Out 1.2 ± 1.3 1.9 ± 0.9 1.5 ± 0.6 2.5 ± 1.5 1.7 ± 0.7 2.3 ± 1.0 16.7 ± 12.0 −1.1 ± 31.2 2.8 ± 1.2 2.4 ± 0.8
In −1.7 ± 1.5 −1.9 ± 0.9 −1.5 ± 0.6 −2.9 ± 1.7 −1.7 ± 0.6 −1.8 ± 1.0 −18.1 ± 15.7 −8.9 ± 4.4 −2.2 ± 1.0 −2.3 ± 0.8
0.5 Out 2.0 ± 2.4 3.8 ± 1.7 3.1 ± 1.3 5.4 ± 3.1 3.5 ± 1.1 4.4 ± 1.9 33.1 ± 22.8 9.3 ± 35.5 5.4 ± 2.2 4.8 ± 1.7
In −4.0 ± 3.1 −3.9 ± 1.6 −3.1 ± 1.2 −5.6 ± 3.0 −12.2 ± 27.4 −4.0 ± 1.9 −33.6 ± 25.3 −17.9 ± 8.8 −5.0 ± 1.8 −4.5 ± 1.5
1 Out 2.7 ± 3.4 6.6 ± 2.9 5.6 ± 2.3 9.1 ± 5.7 6.1 ± 1.6 7.6 ± 3.2 40.1 ± 56.1 21.3 ± 40.7 9.4 ± 4.0 7.9 ± 2.9
In −10.1 ± 6.4 −7.1 ± 2.8 −5.6 ± 2.2 −9.1 ± 5.1 −5.8 ± 1.3 −7.0 ± 3.2 −50.3 ± 29.6 −32.8 ± 16.8 −8.5 ± 3.1 −7.5 ± 2.8
Shift −0.4 ± 1.8 −1.3 ± 2.2 0.1 ± 0.6 −1.3 ± 4.1 0.4 ± 1.4 0.9 ± 1.5 1.3 ± 5.6 −0.5 ± 2.0 0.1 ± 2.0 −2.0 ± 6.0
2 Out 3.4 ± 4.6 12.3 ± 5.4 10.9 ± 4.5 17.8 ± 11.1 12.5 ± 3.0 15.8 ± 7.9 85.6 ± 86.9 49.8 ± 54.7 19.0 ± 8.1 15.6 ± 5.6
In −40.0 ± 19.2 −15.1 ± 5.6 −11.5 ± 4.4 −17.2 ± 9.0 −11.8 ± 2.7 −13.8 ± 6.3 −68.8 ± 35.1 −62.0 ± 30.6 −17.5 ± 6.5 −14.7 ± 4.9
Shift −2.4 ± 3.4 −3.0 ± 3.3 −0.1 ± 1.1 −2.1 ± 6.5 0.7 ± 2.6 2.5 ± 3.7 2.8 ± 9.5 −2.8 ± 5.5 0.1 ± 4.3 −0.7 ± 1.7
3 Shift −6.9 ± 5.4 −6.8 ± 5.6 −1.1 ± 1.8 −3.1 ± 8.7 1.4 ± 4.4 5.1 ± 6.0 1.1 ± 12.8 −5.4 ± 7.0 0.4 ± 7.2 −1.2 ± 2.5
Abbreviations: MLC multi-leaf collimator, SBRT stereotactic body radiation therapy, Vn% the volume irradiated at least n% of prescribed dose, Max maximum dose, Dn% the dose received by the n% volume of the
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of the original plan since the sizes of MLC apertures
were reduced. By introducing MLC errors of 0.5 mm,
the averaged values of V90%, D95% and mean dose to tar-
get were decreased by 4%, 3.9% and 3.1%, respectively.
In the case of Class Shift, the values of V90% and D95%
for the target were decreased. By introducing MLC er-
rors of 3 mm, the averaged values of V90% and D95% for
the target were decreased by 6.9% and 6.8%, respectively
and the averaged value of maximum dose delivered to
the ribs was increased by 5.1%. A radiation oncologist
whose specialty is lung SBRT comprehensively reviewed
the changed DVHs and concluded that 0.25 mm MLC
misalignment in the case of Class In and Class Out, and
1 mm misalignment for Class Shift were clinically
tolerable.
Dose-volumetric changes with respect to the magnitudes
of MLC misalignments for spine SBRT plans
The percent differences of dose-volumetric indicators
with respect to the magnitudes of MLC misalignments
in spine SBRT for Class Out, Class In and Class Shift are
shown in Table 3. Since the kind of OARs which should
be considered was different for each SBRT plan accord-
ing to the tumor location, the evaluated numbers of
plans (N) were not always same. In Class Out, by intro-
ducing MLC errors of 0.5 mm, the averaged value of
V10Gy of spinal cord was increased by 58.9% (N= 3). The
averaged value of maximum dose delivered to the
esophagus was increased by 10.3% (N = 2). In the case of
Class In, with MLC errors of 0.5 mm, the averaged
values of V100% and D95% of the target were decreased by
15% and 4.1%, respectively (N= 8 and N= 10). In the
case of Class Shift, the value of V100% of the target was
decreased by 5.4% (N = 8) when introducing MLC errors
of 3 mm. With MLC errors of 1 mm, the averaged
values of V10Gy of spinal cord (N = 3), V14Gy of cauda
equina (N = 1) and the maximum dose to brain stem (N
= 1) were increased by 36.8%, 123.9% and 11.8%, respect-
ively. A radiation oncologist whose specialty is spine
SBRT comprehensively reviewed the changed DVHs and
concluded that 0.25 mm MLC misalignment in the case
of Class In and Class Out, and 1 mm misalignment for
Class Shift were clinically tolerable.
An extreme example of the DVH changes of a lung
and spine SBRT plan by the introduction of the max-
imum MLC misalignments in this study is shown in
Figure 3.
Ability of gamma criteria to detect the dose-volumetric
changes in lung SBRT plans
The gamma criteria of 1.5%/1.5 mm, 1%/2 mm and 2%/
2 mm with 90% passing rate were unable to detect in-
creases of 33.1% and 9.3% of extra lung volumeirradiated to at least 12.4 Gy and 11.6 Gy, respectively.
These criteria were also unable to detect an increase in
the maximum delivered dose to the trachea, spinal cord
and ribs by amounts of 5.4%, 3.5% and 4.4%, respect-
ively. Furthermore, decreases in V90% and D95% for the
target volume of 4% and 3.9% were not detected with
those gamma criteria. On the other hand, the gamma
criteria of 1%/1 mm and 2%/1 mm were able to detect
the dose-volumetric changes previously mentioned.
Ability of gamma criteria to detect the dose-volumetric
changes in spine SBRT plans
The gamma criteria of 1.5%/1.5 mm, 1%/2 mm and 2%/
2 mm with 90% passing rate were unable to detect in-
creases of 58.9% and 356.3% in the V10Gy of the spinal
cord and the V14Gy of the cauda equina, respectively.
These criteria were also unable to detect an increase in
the maximum delivered dose to the esophagus, brain-
stem and bowel by amounts of 10.3%, 12.1% and 2.7%,
respectively. Furthermore, decreases in V100% and D95%
for the target volume of 15% and 4.1% were not detected
with those criteria. On the other hand, the gamma cri-
teria of 1%/1 mm and 2%/1 mm were able to detect the
dose-volumetric changes previously mentioned.
Correlations between dose-volumetric changes and
gamma passing rates
No correlations were observed between dose-volumetric
changes and gamma passing rates using either Map-
CHECK2 or EBT2 films with every criterion in both
lung and spine SBRT plans (always γ < 0.4).
Sensitivity and specificity
The ROC curves and the values of AUC are shown in
Figure 4 and Table 4, respectively. Since we determined
that clinically perturbed dose distributions appear from
0.5 mm MLC misalignments in Class In and Class Out
and at 2 mm in Class shift, only those data are pre-
sented. In the case of MapCHECK2, 1%/1 mm showed
the best performance in Class Out, and showed the
worst performance in Class Shift. The gamma criterion
of 1.5%/1.5 mm showed the best performance in Class
Shift. The criterion of 2%/1 mm showed the best per-
formance in Class In and the second best performance
in Class Shift. In the case of EBT2 film, 2%/1 mm
showed the best performance and 1%/1 mm showed the
second best performance in Class In and Class Shift. For
Class Out, 1%/1 mm showed the best performance and
2%/1 mm showed the second best performance.
Discussion
In this study, the gamma-index method criterion for
SBRT VMAT plans that could achieve greater than 90%
passing rates in original error free plans, while showing
Table 3 The changes of dose-volumetric indicators according to the magnitudes of MLC misalignments in spine SBRT plans
Percent differences compared to the original plan (%)
MLC error (mm) Class Target Organs at risk
V100% D95% Mean SC V10Gy Esophagus Max Cauda equina V14Gy Brainstem Max Bowel Max
N 8 10 10 3 2 1 1 5
0.25 Out 5.1 ± 2.2 2.4 ± 1.2 1.6 ± 0.7 28.5 ± 9.2 4.0 ± 1.0 133 7.4 1.4 ± 0.3
In −6.6 ± 4.8 −1.9 ± 1.2 −1.6 ± 0.7 −22.9 ± 3.7 −5.5 ± 3.2 −45.9 −1.9 −1.3 ± 0.4
0.5 Out 10.0 ± 5.1 4.5 ± 2.2 3.1 ± 1.4 58.9 ± 13.4 10.3 ± 5.3 356.3 12.1 2.7 ± 0.7
In −15.0 ± 7.7 −4.1 ± 2.3 −3.2 ± 1.4 −44.7 ± 6.8 −10.9 ± 7.0 −70.5 −7.4 −2.7 ± 0.7
1 Out 16.7 ± 9.3 7.2 ± 3.6 5.6 ± 2.5 113.9 ± 28.3 20.5 ± 12.2 610.6 19.5 4.8 ± 1.3
In −32.2 ± 13.6 −7.7 ± 4.0 −5.8 ± 2.6 −71.7 ± 7.4 −19.0 ± 11.5 −91.8 −14.8 −4.8 ± 1.3
Shift 0.2 ± 1.5 1.1 ± 1.2 0.2 ± 0.3 36.8 ± 18.7 −9.6 ± 11.3 123.9 11.8 −2.4 ± 1.5
2 Out 28.5 ± 18.2 13.3 ± 6.4 10.9 ± 5.0 244.4 ± 41.9 45.0 ± 30.0 910.4 36.8 10.3 ± 1.8
In −65.5 ± 22.5 −16.6 ± 8.3 −11.8 ± 5.2 −98 ± 1.9 −33.8 ± 18.0 −100 −30.1 −9.3 ± 2.5
Shift −2.3 ± 2.8 −0.2 ± 1.9 −0.1 ± 0.7 66.4 ± 16.3 −15.2 ± 16.9 346.1 19.9 −4.3 ± 1.9
3 Shift −5.4 ± 5.3 −3.3 ± 3.7 −0.8 ± 1.1 109.3 ± 23.5 −19.6 ± 20.0 628.3 27.6 −5.3 ± 2.5
Abbreviations: MLC multi-leaf collimator, SBRT stereotactic body radiation therapy, Vn% the volume irradiated at least n% of prescribed dose, SC spinal cord, Max maximum dose, Dn% the dose received by the n% volume of the
















Figure 3 Variation of dose volume histograms (DVH) due to the MLC misalignments. Dose volume histograms (DVH) of a lung stereotactic
body radiation therapy (SBRT) plan (a) and a spine SBRT plan (b) are shown. The DVHs from the original plan and the plans with multi-leaf
collimator (MLC) misalignments of Class Out, Class In and Class Shift are shown. At Class Out and Class In, MLC misalignments of 2 mm were
introduced while 3 mm errors were introduced at Class Shift.
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misalignments were investigated. Dose-volumetric changes
were reviewed by a radiation oncologist from a clinical
point of view and it was determined that Class In and Class
Out modified plans with a 0.5 mm MLC misalignment, and
Class Shift with a 2 mm misalignment were clinically un-
acceptable. In order to detect those MLC misalignments,
the criterion of 2%/1 mm with 90% passing rate as a toler-
ance level seemed to satisfy the requirements mentioned
above for MapCHECK2. The EBT2 films could satisfy the
requirements when using gamma criterion of 2%/1 mm
with a passing rate of 80%. The conventional 2%/2 mm cri-
terion, widely-adopted in the clinic for SBRT plans, was not
sensitive enough to detect MLC misalignments which may
potentially impair the quality of treatment.
The most stringent criterion in this study, 1%/1 mm,
seemed inappropriate since the original plan already failed,
with passing rates less than the required 90%. In spite of
the careful calibration of measuring devices as well as the
institutional validation of TrueBeam STx and TPS before
measurements, inherent uncertainties still existed in the
original plans. Furthermore, setup uncertainties were also
included in the results. Since these uncertainties could not
be completely removed practically, when applying the cri-
terion of 1%/1 mm, they may have influenced the gamma
passing rates which were less than 90%. On the other
hand, Poppe et al. demonstrated that statistical fluctua-
tions and systematic errors are dominant when using 1%/
1 mm criteria [24]. Similarly, Heilemann et al. didn’t rec-
ommend to use 1%/1 mm criteria [13]. Therefore, in order
to use the criterion of 1%/1 mm, a careful approach isnecessary and a different tolerance level should be estab-
lished instead of 90%, as used in this study.
In the case of EBT2 film, in spite of excellent spatial reso-
lution, the inherent uncertainty (approximately ±5%) is lar-
ger than the MapCHECK2 uncertainty [25,26]. The highest
gamma criterion for dose used in this study was 1%, which
was much lower than the uncertainty of EBT2 film. For this
reason, the passing rates of the majority of the original
plans were lower than 90% which is used as a tolerance
level in the present study. In addition, the film to the calcu-
lated dose distribution registration in RIT113 program was
done by fitting the gradients automatically resulting best
match between the calculated and measured dose distribu-
tions. Therefore, 2D gamma analysis using EBT2 film was
only an analysis of the dose distribution not of the overall
accuracy of the system. However, the detecting ability of
EBT2 film was found to be similar to MapCHECK2 as
shown in Table 1. Moreover, gamma criterion of 2%/1 mm
with a passing rate of 80% when using EBT2 film showed
similar performance with that of 2%/1 mm with a passing
rate of 90% when using MapCHECK2.
The sensitivities of gamma-index method to the MLC
misalignments with various criteria were generally
higher in the lung SBRT plans than spine SBRT plans.
As previously studied by LoSasso et al. [17], since the
lung target volumes were generally smaller than the
spine target volumes, the sensitivity to the MLC mis-
alignments was higher in the lung plans, in accordance
with previous studies [13,17]. However, the magnitudes
of the differences were smaller than those of previous
studies since the differences in target volume between
Figure 4 Receiver operating characteristic curve of various gamma criteria when using MapCHECK2 and EBT2 film. Receiver operating
characteristic (ROC) curves of gamma criteria of 1%/1 mm, 1.5%/1.5 mm, 1%/2 mm, 2%/1 mm and 2%/2 mm are shown. The ROC curves of
0.5 mm MLC misalignment at Class Out (a), Class In (c) and 2 mm MLC misalignment at Class Shift (e) when using MapCHECK2 are shown.
Similarly, 0.5 mm MLC misalignment at Class Out (b), Class In (d) and 2 mm MLC misalignment at Class Shift (f) when using EBT2 films
are shown.
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pared to the previous studies [13,15].
Wagner and Vorwerk have suggested an increase of
the tolerance level to up to 99% with conventional cri-
terion instead of altering the criterion for the sensitive
gamma-index method [9]. However, the results in this
study show that increasing the tolerance level would notguarantee detection of small misalignments of the MLC.
Similarly, Heilemann et al. demonstrated that the use of
more stringent criterion rather than an increase of toler-
ance level would be beneficial [13].
No correlations between gamma passing rates and dose-
volumetric changes were observed as previous studies have
already shown in IMRT and VMAT cases [13,15,27,28].
Table 4 Area under curve (AUC) values for each gamma criterion when introducing 0.5 mm MLC misalignment in class
in and class out and 2 mm MLC misalignment in class shift
MapCHECK2 EBT2 film
Gamma criterion Class In (0.5 mm) Class Out (0.5 mm) Class Shift (2 mm) Class In (0.5 mm) Class Out (0.5 mm) Class Shift (2 mm)
1%/1 mm 0.909 0.899 0.935 0.853 0.933 0.905
1.5%/1.5 mm 0.920 0.873 0.974 0.788 0.858 0.89
1%/2 mm 0.843 0.890 0.954 0.758 0.813 0.805
2%/1 mm 0.930 0.848 0.968 0.865 0.925 0.933
2%/2 mm 0.883 0.719 0.958 0.783 0.824 0.873
Kim et al. Radiation Oncology 2014, 9:167 Page 11 of 12
http://www.ro-journal.com/content/9/1/167Therefore, even though gamma-index is a convenient indi-
cator for evaluation of patient-specific QA results, careful
analysis of dose distributions should be completed by visual
inspection by the physicist and clinician.
The results of the ROC curves and the values of AUC
did not indicate a single gamma criterion as the ideal cri-
terion in terms of sensitivity and specificity when clinically
perturbed dose distributions began to appear in Class In,
Class Out and Class Shift errors. The criterion of 2%/
1 mm showed generally superior performance to the
others when using both MapCHECK2 and EBT2 film al-
though it was not always the best.
The results showed that small amounts of introduced
MLC misalignments, even within the 1 mm specified by
the manufacturer, hampered the plan quality severely.
This is because the introduced MLC misalignments were
systematic errors and not random errors. Entire MLCs
were shifted in the present study, however this is not ne-
cessarily a realistic situation. Since the aim of this study
is to investigate the ability of various gamma criteria to
detect clinically unacceptable SBRT plans, and not to
simulate real situations, we introduced systematic MLC
misalignments which decreases plan quality.
In the present study, we adopted the global gamma-
index method which is limited in its ability to review low
dose regions. This limitation can potentially lead to misin-
terpretation of the delivered dose to OARs. Therefore, in
the present study, radiation oncologists reviewed the
changes in DVHs of modified plans and determined how
much systematic MLC misalignment is clinically tolerable.
As recommended by Heilemann et al., gamma passing
rates are a good indicator for making a preliminary
decision, however physicists have to evaluate the dose dis-
tribution carefully especially when using global gamma-
index method.
One limitation of the present study is that the mea-
sured data were acquired with only MapCHECK2 and
EBT2 films. The results in this study should not be dir-
ectly applied to other patient-specific QA systems which
use different measuring devices. However, we recom-
mend that the gamma criterion of 2%/2 mm should be
carefully examined, and alternatives considered for
VMAT QA for SBRT.Heilemann et al. and Fredh et al. have investigated
appropriate criterion for 2D patient-specific QA in H&N,
brain and prostate VMAT plans [13,14]. They have demon-
strated that 2%/2 mm is a suitable criterion for fractionated
VMAT QA. In this study, the appropriate criterion for the
patient-specific VMAT QA for SBRT has been investigated
[13,14]. The main difference between the present and previ-
ous studies is that we investigated specifically for SBRT QA
using the VMAT technique. The SBRT plans should be de-
livered more accurately than conventional fractionated radi-
ation therapy [18]. Therefore the gamma evaluation for
SBRT requires more stringent criterion, however this criter-
ion is not yet standardized. We recommend 2%/1 mm as
an appropriate criterion for the gamma-index method for
SBRT when using MapCHECK2 or EBT2 films.
Conclusions
This study demonstrated that the widely clinically adopted
gamma criterion of 2%/2 mm for patient-specific SBRT
QA is not sensitive enough to evaluate the quality of
VMAT plans for SBRT. When using the gamma-index
method for SBRT VMAT QA, an appropriate gamma cri-
terion for each QA system, which is able to detect errors
that hamper plan quality should be established. It is rec-
ommended that 2%/1 mm be used as a criterion with tol-
erance levels for gamma passing rates of 90% and 80%
when using MapCHECK2 and EBT2 films, respectively.
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